Tumor Necrosis Factor Related Activation Protein Uses, Dosage, Side Effects and more
Tumor Necrosis Factor Related Activation Protein is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
Trade Name | Tumor Necrosis Factor Related Activation Protein |
Generic | Dapirolizumab pegol |
Dapirolizumab pegol Other Names | Dapirolizumab pegol, Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |